Particle.news
Download on the App Store
7 ARTICLES
·
1h ago

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Image
Image
Pfizer will pay $150m upfront with more than $1.9bn available for YaoPharma, based on the drug achieving development, regulatory and commercial milestones. Image credit: ShU studio / Shutterstock.com.
Image

Overview

  • Pfizer secured exclusive worldwide rights to develop, manufacture and commercialize YP05002, paying $150 million upfront with up to about $1.94 billion in potential milestones plus tiered royalties.
  • YP05002 is a small‑molecule GLP‑1 receptor agonist in Phase 1 testing in Australia, where YaoPharma, a Fosun Pharma subsidiary, will complete the ongoing trial.
  • Pfizer will assume later-stage development and plans combination studies pairing YP05002 with its Phase 2 GIPR antagonist, PF‑07976016.
  • The move expands Pfizer’s cardiometabolic portfolio following its acquisition of Metsera after earlier setbacks with internal oral GLP‑1 programs.
  • Rivals Novo Nordisk and Eli Lilly remain ahead with near‑term FDA decisions on oral contenders, and analysts note limited public data on YP05002 and a multi‑year path before potential patient use.